[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transitional-cell-carcinoma-of-renal-pelvis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transitional-cell-carcinoma-of-renal-pelvis":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100506479",false,"NCT05874921","uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","uTRACT","Inclusion Criteria:\n\n* Adults \\>18 years old and capable of giving informed consent.\n* Diagnosis of UTUC.\n* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).\n\nExclusion Criteria:\n\n* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).\n* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).\n* Pregnancy or lactation.\n* Unable to comply with protocol requirements (for prospective data capture).\n* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.",[25,26,27,28,29,30,31,32],"Urothelial Carcinoma","Urothelial Carcinoma Recurrent","Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma of the Renal Pelvis and Ureter","Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59],"Upper Tract Urothelial Cancer","UTUC","UGN-101","Mitomycin C","TCC","Ureteral","Upper Tract","Carcinoma","Kidney","Renal","Gel","Local","Prolonged Release","Slow Release","Kidney Sparing","Recurrence","Neoplasms by Histologic Type","Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Neoplasms by Site","Antibiotics, Antineoplastic","Antineoplastic Agents","Alkylating Agents","Nucleic Acid Synthesis Inhibitors","Enzyme Inhibitors","RECRUITING","2025-02-25",{"date":63,"type":64},"2025-02-28","ACTUAL",{"date":66,"type":64},"2023-11-17",{"date":68,"type":20},"2028-01",{"name":70,"class":71},"UroGen Pharma Ltd.","INDUSTRY",22,""]